Roger M. Perlmutter

Last updated
Roger M. Perlmutter
Nationality American
Alma mater Reed College
Washington University
Known forHead of research at Amgen and Merck
Scientific career
Fields Immunology
Institutions Merck Research Laboratories
Academic advisors Joseph Davie

Roger M. Perlmutter is the former executive vice president of Merck & Co. and former president of Merck Research Laboratories. He is currently a non-executive director of Merck Research Laboratories. [1] [2]

Contents

Education and career

He graduated from Reed College and earned his MD and PhD from Washington University in St. Louis in 1979. He did his clinical training in internal medicine at Massachusetts General Hospital and University of California, San Francisco. [3] In 1981, he joined the Division of Biology at the California Institute of Technology before joining the University of Washington in 1984 to join the medicine and biochemistry department. At Caltech he worked closely with Leroy Hood, an important immunologist and later recruited Hood to the University of Washington to serve as founding professor of the Department of Molecular Biotechnology. [4]

In 1989, he was the founding chair of the immunology department. His research focused on the role of tyrosine kinase signaling and its role in lymphocyte development and immunology. [5] During that time he was also a Howard Hughes Medical Institute (HHMI) investigator. [6] [7]

In 1997, Perlmutter joined Merck Research Laboratories as the executive vice president of basic and preclinical research. At the time, Perlmutter was not chosen to replace Edward Scolnik as president of Merck Research Laboratories; that position went instead to Peter S. Kim, previously of the Massachusetts Institute of Technology. In 2001, Perlmutter left Merck and joined Amgen as the executive vice president and head of R&D from January 2001 to February 2012. In 2013, he replaced Peter S. Kim as the executive vice president and president of Merck Research Laboratories. [8] In 2020, he retired from Merck and was replaced by Dean Y. Li. [9] In 2021 he became CEO of a microscopy start-up, Eikon Therapeutics. [10]

He was the president of the American Association of Immunologists from 1999 to 2000 and a fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science. He also serves on the boards of the Institute for Systems Biology and StemCells Inc [11] and is a science partner at The Column Group, a venture capital fund focused on biotechnology. [12]

Related Research Articles

<span class="mw-page-title-main">Leroy Hood</span> American biologist (born 1938)

Leroy "Lee" Edward Hood is an American biologist who has served on the faculties at the California Institute of Technology (Caltech) and the University of Washington. Hood has developed ground-breaking scientific instruments which made possible major advances in the biological sciences and the medical sciences. These include the first gas phase protein sequencer (1982), for determining the sequence of amino acids in a given protein; a DNA synthesizer (1983), to synthesize short sections of DNA; a peptide synthesizer (1984), to combine amino acids into longer peptides and short proteins; the first automated DNA sequencer (1986), to identify the order of nucleotides in DNA; ink-jet oligonucleotide technology for synthesizing DNA and nanostring technology for analyzing single molecules of DNA and RNA.

<span class="mw-page-title-main">Wistar Institute</span> American biomedical research institute

The Wistar Institute is an independent, nonprofit research institution in biomedical science with special focuses in oncology, immunology, infectious disease and vaccine research. Located on Spruce Street in Philadelphia’s University City neighborhood, Wistar was founded in 1892 as a nonprofit institution to focus on biomedical research and training.

<span class="mw-page-title-main">President's Council of Advisors on Science and Technology</span> White House advisory board

The President's Council of Advisors on Science and Technology (PCAST) is a council, chartered in each administration with a broad mandate to advise the president of the United States on science and technology. The current PCAST was established by Executive Order 13226 on September 30, 2001, by George W. Bush, was re-chartered by Barack Obama's April 21, 2010, Executive Order 13539, by Donald Trump's October 22, 2019, Executive Order 13895, and by Joe Biden's February 1, 2021, Executive Order 14007.

Charles Thomas Caskey, also known as C. Thomas Caskey, was an American internist who has been a medical Geneticist and biomedical researcher and entrepreneur. He was a Professor of Molecular and Human Genetics at Baylor College of Medicine, and served as editor of the Annual Review of Medicine from 2001 to 2019. He was a member of the editorial boards of the Proceedings of the National Academy of Sciences, Science, the Encyclopedia of Molecular Medicine and numerous other medical and scientific journals.

<span class="mw-page-title-main">PTK2</span> Protein-coding gene in humans

PTK2 protein tyrosine kinase 2 (PTK2), also known as focal adhesion kinase (FAK), is a protein that, in humans, is encoded by the PTK2 gene. PTK2 is a focal adhesion-associated protein kinase involved in cellular adhesion and spreading processes. It has been shown that when FAK was blocked, breast cancer cells became less metastatic due to decreased mobility.

<span class="mw-page-title-main">Peter S. Kim</span> American scientist

Peter S. Kim is an American scientist. He was president of Merck Research Laboratories (MRL) 2003–2013 and is currently Virginia & D.K. Ludwig Professor of Biochemistry at Stanford University, Institute Scholar at Stanford ChEM-H, and Lead Investigator of the Infectious Disease Initiative at the Chan Zuckerberg Biohub.

Margaret L. Kripke is an American immunologist. She is an expert in photoimmunology and the immunology of skin cancers. She earned a BS and MS in bacteriology, and a Ph.D in immunology, at the University of California at Berkeley.

<span class="mw-page-title-main">Edison Liu</span>

Edison T. Liu is an American chemist who is the former president and CEO of The Jackson Laboratory, and the former director of its NCI-designated Cancer Center (2012-2021). Before joining The Jackson Laboratory, he was the founding executive director of the Genome Institute of Singapore (GIS), chairman of the board of the Health Sciences Authority, and president of the Human Genome Organization (HUGO) (2007-2013). As the executive director of the GIS, he brought the institution to international prominence as one of the most productive genomics institutions in the world.

Laurie Hollis Glimcher is an American physician-scientist who was appointed president and CEO of Dana–Farber Cancer Institute in October 2016. She was elected a Member of the American Philosophical Society in 2019.

<span class="mw-page-title-main">James P. Allison</span> American immunologist and Nobel laureate (born 1948)

James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center at the University of Texas.

<span class="mw-page-title-main">Paul B. Rothman</span>

Dr. Paul B. Rothman is the former Frances Watt Baker, M.D., and Lenox D. Baker Jr., M.D., Dean of the Medical Faculty, vice president for medicine at Johns Hopkins University, and former chief executive officer of Johns Hopkins Medicine. As dean and CEO, Dr. Rothman oversaw both the School of Medicine and the Johns Hopkins Health System, which together encompass six hospitals, hundreds of faculty and community physicians and a self-funded health plan.

Jeffrey A. Bluestone is the A.W. and Mary Margaret Clausen Distinguished Professor Emeritus of Metabolism and Endocrinology at the University of California, San Francisco, and was, for a number of years, an earlier executive vice chancellor and provost of that university. He began the UCSF affiliation in 2000, after earlier extended positions at the NCI-NIH, and at The University of Chicago. Bluestone earned his undergraduate and masters degrees in microbiology from Rutgers State University, and his doctoral degree in immunology from Cornell Graduate School of Medical Science. His current research is focused on understanding T cell activation and immune tolerance in autoimmunity and organ transplantation. In April 2016, he co-founded and served as the president and CEO of the Parker Institute for Cancer Immunotherapy,. In 2019, he co-founded and is Chief Executive Officer and President of Sonoma Biotherapeutics.

Edward Scolnick is a core investigator at the Broad Institute, the former founding director of the Stanley Center for Psychiatric Research at Broad Institute, and former head of research and development at Merck Research Laboratories.

<span class="mw-page-title-main">Gary Borisy</span>

Gary G. Borisy is a retired president and director of the Marine Biological Laboratory in Woods Hole, Massachusetts. In 2013, Borisy joined the Department of Microbiology at the Forsyth Institute.

Shenzhen International BT Leadership Summit is a biology-focused business conference. It is held each year in September. It is arranged by the Shenzhen Municipal People's Government. It is held at the Shenzhen Convention and Exhibition Center.

Dean Y. Li is the senior vice president of Discovery Sciences and Translational Medicine of Merck & Co. and president-elect of Merck Research Laboratories.

Kenneth S. Ramos is an American physician-scientist.

Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002. His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews. He has been a top executive at several pharmaceutical companies, with respect to the development and clinical testing of novel anticancer drugs and cell therapies. For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013. Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020, when he became the President of BioNTech US, both pharmaceutical companies headquartered in Cambridge, MA. His honors include being elected a member of the American Society for Clinical Investigation, and the Association of American Physicians.

References

  1. ↑ "Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories". Merck.com. Retrieved 2021-05-06.
  2. ↑ Taylor, Phil (2020-10-05). "Roger Perlmutter leaves Merck after 7 years, joins board at Insitro -". pharmaphorum.com. Retrieved 2021-05-06.
  3. ↑ "Roger M. Perlmutter, M.D., Ph.D." Merck. Retrieved 30 November 2013.
  4. ↑ Timmerman, Luke D. (2016). Hood: Trailblazer of the Genomic Age. Tracy Cutchlow, Robert Simison. [Place of publication not identified]. pp. 230–245. ISBN   978-0-9977093-0-8. OCLC   959626112.{{cite book}}: CS1 maint: location missing publisher (link)
  5. ↑ Turner, JM; Brodsky, MH; Irving, BA; Levin, SD; Perlmutter, RM; Littman, DR (Mar 9, 1990). "Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs". Cell. 60 (5): 755–65. doi:10.1016/0092-8674(90)90090-2. PMID   2107025. S2CID   205019980.
  6. ↑ Dietz, Claire (5 May 2005). "Roger Perlmutter returns to give Krebs Lecture on drug discovery". University of Washington Today. Retrieved 30 November 2013.
  7. ↑ "Roger M. Perlmutter M.D., Ph.D." BusinessWeek. Archived from the original on December 3, 2013. Retrieved 30 November 2013.
  8. ↑ "Merck Announces Appointment of Roger M. Perlmutter, M.D., Ph.D., As President of Merck Research Laboratories; Peter S. Kim, Ph.D., to Retire". 7 March 2013. Archived from the original on 3 December 2013. Retrieved 30 November 2013.
  9. ↑ "Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories". www.businesswire.com. 2 October 2020. Retrieved 2 October 2020.
  10. ↑ "Roger Perlmutter, former Merck R&D head, becomes CEO of startup". STAT. 2021-05-05. Retrieved 2021-05-06.
  11. ↑ "Institute for Systems Biology Names Dr. Roger M. Perlmutter Board Chairman". Institute of Systems Biology. 19 August 2003. Retrieved 30 November 2013.
  12. ↑ "Nobel Prize winners, all-star CEO, big bucks back East Bay biotech's deep dive into cells". www.bizjournals.com. Retrieved 2021-05-28.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.